Literature DB >> 24321314

RHOB influences lung adenocarcinoma metastasis and resistance in a host-sensitive manner.

Diego Luis-Ravelo1, Iker Antón1, Carolina Zandueta1, Karmele Valencia1, María-José Pajares2, Jackeline Agorreta2, Luis Montuenga2, Silvestre Vicent1, Ignacio I Wistuba3, Javier De Las Rivas4, Fernando Lecanda5.   

Abstract

Lung adenocarcinoma (ADC) is the most common lung cancer subtype and presents a high mortality rate. Clinical recurrence is often associated with the emergence of metastasis and treatment resistance. The purpose of this study was to identify genes with high prometastatic activity which could potentially account for treatment resistance. Global transcriptomic profiling was performed by robust microarray analysis in highly metastatic subpopulations. Extensive in vitro and in vivo functional studies were achieved by overexpression and by silencing gene expression. We identified the small GTPase RHOB as a gene that promotes early and late stages of metastasis in ADC. Gene silencing of RHOB prevented metastatic activity in a systemic murine model of bone metastasis. These effects were highly dependent on tumor-host interactions. Clinical analysis revealed a marked association between high RHOB levels and poor survival. Consistently, high RHOB levels promote metastasis progression, taxane-chemoresistance, and contribute to the survival advantage to γ-irradiation. We postulate that RHOB belongs to a novel class of "genes of recurrence" that have a dual role in metastasis and treatment resistance.
Copyright © 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Drug target; GTPase; MMP; Microenvironment; Non-cell autonomous; Radiotheraphy; Tumor-stroma

Mesh:

Substances:

Year:  2013        PMID: 24321314      PMCID: PMC5528549          DOI: 10.1016/j.molonc.2013.11.001

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  52 in total

Review 1.  Actin' up: RhoB in cancer and apoptosis.

Authors:  G C Prendergast
Journal:  Nat Rev Cancer       Date:  2001-11       Impact factor: 60.716

2.  RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage.

Authors:  G J Cerniglia; E J Bernhard; G C Prendergast
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

3.  Activation of RhoB by hypoxia controls hypoxia-inducible factor-1alpha stabilization through glycogen synthase kinase-3 in U87 glioblastoma cells.

Authors:  Nicolas Skuli; Sylvie Monferran; Caroline Delmas; Isabelle Lajoie-Mazenc; Gilles Favre; Christine Toulas; Elizabeth Cohen-Jonathan-Moyal
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

Review 4.  Rho GTPases: biochemistry and biology.

Authors:  Aron B Jaffe; Alan Hall
Journal:  Annu Rev Cell Dev Biol       Date:  2005       Impact factor: 13.827

5.  PRK1 is targeted to endosomes by the small GTPase, RhoB.

Authors:  H Mellor; P Flynn; C D Nobes; A Hall; P J Parker
Journal:  J Biol Chem       Date:  1998-02-27       Impact factor: 5.157

Review 6.  Rho GTPases in transformation and metastasis.

Authors:  Aron B Jaffe; Alan Hall
Journal:  Adv Cancer Res       Date:  2002       Impact factor: 6.242

7.  Critical role of Rho in cell transformation by oncogenic Ras.

Authors:  G C Prendergast; R Khosravi-Far; P A Solski; H Kurzawa; P F Lebowitz; C J Der
Journal:  Oncogene       Date:  1995-06-15       Impact factor: 9.867

8.  RhoB is dispensable for mouse development, but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells.

Authors:  A X Liu; N Rane; J P Liu; G C Prendergast
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

9.  WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis.

Authors:  Don X Nguyen; Anne C Chiang; Xiang H-F Zhang; Juliet Y Kim; Mark G Kris; Marc Ladanyi; William L Gerald; Joan Massagué
Journal:  Cell       Date:  2009-07-02       Impact factor: 41.582

10.  Wnt5a control of cell polarity and directional movement by polarized redistribution of adhesion receptors.

Authors:  Eric S Witze; Elizabeth S Litman; Gretchen M Argast; Randall T Moon; Natalie G Ahn
Journal:  Science       Date:  2008-04-18       Impact factor: 47.728

View more
  16 in total

1.  Farnesyltransferase Inhibition Exacerbates Eosinophilic Inflammation and Airway Hyperreactivity in Mice with Experimental Asthma: The Complex Roles of Ras GTPase and Farnesylpyrophosphate in Type 2 Allergic Inflammation.

Authors:  Jennifer M Bratt; Kevin Y Chang; Michelle Rabowsky; Lisa M Franzi; Sean P Ott; Simone Filosto; Tzipora Goldkorn; Muhammad Arif; Jerold A Last; Nicholas J Kenyon; Amir A Zeki
Journal:  J Immunol       Date:  2018-04-27       Impact factor: 5.422

Review 2.  Transcriptional and post-transcriptional regulation of the genes encoding the small GTPases RhoA, RhoB, and RhoC: implications for the pathogenesis of human diseases.

Authors:  Eirini Nomikou; Melina Livitsanou; Christos Stournaras; Dimitris Kardassis
Journal:  Cell Mol Life Sci       Date:  2018-03-02       Impact factor: 9.261

3.  Construction and analysis of three networks of genes and microRNAs in adenocarcinoma.

Authors:  Jiahui Ning; Xiaoxin Guo; Ning Wang; Luchen Xue
Journal:  Oncol Lett       Date:  2015-09-03       Impact factor: 2.967

4.  Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-mediated Effects.

Authors:  Daniel Ajona; Carolina Zandueta; Leticia Corrales; Haritz Moreno; María J Pajares; Sergio Ortiz-Espinosa; Elena Martínez-Terroba; Naiara Perurena; Fernando J de Miguel; Eloisa Jantus-Lewintre; Carlos Camps; Silvestre Vicent; Jackeline Agorreta; Luis M Montuenga; Ruben Pio; Fernando Lecanda
Journal:  Am J Respir Crit Care Med       Date:  2018-05-01       Impact factor: 21.405

5.  Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer.

Authors:  Borja Ruiz-Fernández de Córdoba; Haritz Moreno; Fernando Lecanda; Rafael Martínez-Monge; Karmele Valencia; Naiara Perurena; Pablo Ruedas; Thomas Walle; Alberto Pezonaga-Torres; Juan Hinojosa; Elisabet Guruceaga; Antonio Pineda-Lucena; Marta Abengózar-Muela; Denis Cochonneau; Carolina Zandueta; Susana Martínez-Canarias; Álvaro Teijeira; Daniel Ajona; Sergio Ortiz-Espinosa; Xabier Morales; Carlos Ortiz de Solórzano; Marta Santisteban; Luis I Ramos-García; Laura Guembe; Vratislav Strnad; Dominique Heymann; Sandra Hervás-Stubbs; Rubén Pío; María E Rodríguez-Ruiz; Carlos E de Andrea; Silvestre Vicent; Ignacio Melero
Journal:  Cancer Discov       Date:  2022-05-02       Impact factor: 38.272

6.  Critical functions of RhoB in support of glioblastoma tumorigenesis.

Authors:  Yufang Ma; Yuanying Gong; Zhixiang Cheng; Sudan Loganathan; Crystal Kao; Jann N Sarkaria; Ty W Abel; Jialiang Wang
Journal:  Neuro Oncol       Date:  2014-09-12       Impact factor: 12.300

7.  miRNA cargo within exosome-like vesicle transfer influences metastatic bone colonization.

Authors:  Karmele Valencia; Diego Luis-Ravelo; Nicolas Bovy; Iker Antón; Susana Martínez-Canarias; Carolina Zandueta; Cristina Ormazábal; Ingrid Struman; Sébastien Tabruyn; Vera Rebmann; J De Las Rivas; Elisabet Guruceaga; Eva Bandrés; Fernando Lecanda
Journal:  Mol Oncol       Date:  2014-02-06       Impact factor: 6.603

Review 8.  Rho GTPases in cancer radiotherapy and metastasis.

Authors:  Rui-Jie Zeng; Chun-Wen Zheng; Wan-Xian Chen; Li-Yan Xu; En-Min Li
Journal:  Cancer Metastasis Rev       Date:  2020-08-08       Impact factor: 9.264

Review 9.  Progression and metastasis of lung cancer.

Authors:  Helmut H Popper
Journal:  Cancer Metastasis Rev       Date:  2016-03       Impact factor: 9.264

10.  Sp1-driven up-regulation of miR-19a decreases RHOB and promotes pancreatic cancer.

Authors:  Yonggang Tan; Hongzhuan Yin; Heying Zhang; Jun Fang; Wei Zheng; Dan Li; Yue Li; Wei Cao; Cheng Sun; Yusi Liang; Juan Zeng; Huawei Zou; Weineng Fu; Xianghong Yang
Journal:  Oncotarget       Date:  2015-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.